Developmental and Epileptic Encephalopathy Treatment Study
A Phase 2, multicenter, open-label, long-term safety study of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201 and are candidates for continuous treatment for up to 52 weeks
- Sex at Birth: Any
- Age: Adult (18 - 64)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase II
- Conditions Being Studied: Brain and Nervous System, Epilepsy
Study Purpose
LP352 is being studied to see if it might reduce the number of seizures in patients with DEE. LP352 is thought to work by activating specific sites in the brain that are associated with seizure disorders. The main goal of this study is to learn how safe different doses of LP352 are when taken for a longer period of time.
Who Can Participate
Age: 18-65
Locations
UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106
- UH IRB: STUDY20221452
- StudyID: 2022-01052
- ClinicalTrials.gov: NCT05626634
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422